Core Viewpoint - Yiling Pharmaceutical has received a formal acceptance notice from the National Medical Products Administration for its new drug registration application of "Xiaoer Lianhua Qinggan Granules," indicating progress in the company's innovative drug development for pediatric use [1] Group 1: Product Information - "Xiaoer Lianhua Qinggan Granules" is an innovative traditional Chinese medicine developed by the company [1] - The drug is indicated for the treatment of acute upper respiratory tract infections in children, specifically for symptoms such as fever, nasal congestion, sore throat, cough, aversion to wind, sneezing, runny nose, headache, muscle aches, pale red or red tongue, thin yellow coating, and floating rapid pulse [1]

Core Viewpoint - Yiling Pharmaceutical has received formal acceptance for its new drug registration application for "Children's Lianhua Qingwen Granules" from the National Medical Products Administration, indicating progress in its product development and potential market entry [1] Company Summary - Yiling Pharmaceutical is focused on innovative traditional Chinese medicine, with "Children's Lianhua Qingwen Granules" being a self-developed product aimed at treating acute upper respiratory infections in children [1] - The granules are designed to alleviate symptoms such as fever, nasal congestion, sore throat, cough, and muscle aches, showcasing the company's commitment to addressing pediatric health issues [1] Industry Summary - The acceptance of the new drug application reflects the growing interest and regulatory support for traditional Chinese medicine in the pharmaceutical industry, particularly in the context of respiratory illnesses [1] - The product targets a specific market segment (children) which may enhance its competitive positioning within the broader healthcare landscape [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，石家庄以岭药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局下发的《受理通知书》，由公司提交的"小儿连花清感颗粒"新药注册 上市申请已获正式受理。现就相关事项公告如下： 一、受理通知书基本内容 申 请 人：石家庄以岭药业股份有限公司 申请事项：境内生产药品注册上市许可 证券代码：002603 证券简称：以岭药业 公告编号：2025-030 石家庄以岭药业股份有限公司 关于收到药品注册申请受理通知书的公告 小儿连花清感颗粒是公司自主研制的中药创新药，其功能主治为：清感解表， 宣肺泄热。用于儿童急性上呼吸道感染风热感冒证，症见发热，鼻塞，咽喉肿痛， 咳嗽，恶风，喷嚏、流涕，头痛，肌肉酸痛，舌淡红或红，苔薄黄，脉浮数。 三、对公司的影响及主要风险提示 根据国家药品注册相关的法律法规要求，上述药品在获国家药品监督管理局 注册申请受理后将转入国家药品监督管理局药品审评中心接受技术审评、现场核 查、抽样检验等一系列环节，完成时间、审批结果均具有一定的不确定性，因此 上述产品获得注册受理对公司近期业绩不会产生影 ...

人民财讯8月19日电，以岭药业（002603）8月19日晚间公告，公司近日收到国家药品监督管理局下发的 《受理通知书》，公司提交的"小儿连花清感颗粒"新药注册上市申请已获正式受理。该药品是公司自主 研制的中药创新药，其功能主治为：清感解表，宣肺泄热。用于儿童急性上呼吸道感染风热感冒证。 ...

以岭药业公告称，公司收到国家药品监督管理局下发的《受理通知书》，公司提交的"小儿连花清感颗 粒"新药注册上市申请已获正式受理。该药品为公司自主研制的中药创新药，功能主治为清感解表，宣 肺泄热，用于儿童急性上呼吸道感染风热感冒证。 ...

Group 1 - Yiling Pharmaceutical (002603) signed a cooperation agreement with Ant Group's healthcare division on August 17 [1] - The collaboration aims to integrate resources from both companies to focus on patient needs [1] - The goal is to create a leading digital content ecosystem in the pharmaceutical and health sector in China [1]

Group 1 - The core viewpoint of the news is the strong performance of the Chinese traditional medicine sector, highlighted by the rise of the Zhongzheng Traditional Chinese Medicine Index and its constituent stocks following a new policy from the Liaoning Provincial Medical Insurance Bureau [1][2] - The Zhongzheng Traditional Chinese Medicine Index (930641) increased by 1.62%, with notable gains from Tian Shili (600535) up 8.03%, Xin Tian Pharmaceutical (002873) up 7.01%, and Da Ren Tang (600329) up 6.07% [1] - The new policy includes the integration and regulation of three types of medical service pricing, specifically incorporating 39 medical service items, including "traditional Chinese medicine plaster," into the provincial basic medical insurance and work injury insurance fund payment scope, effective from August 20, 2025 [1] Group 2 - Dongwu Securities indicates that the innovative drug industry in China has reached a turning point, with significant advancements in both policy and research and development [2] - The policy framework, including the "Full Chain Support for Innovative Drug Development Implementation Plan," provides support across payment, approval, and financing sectors, facilitating industry growth [2] - As of Q1 2025, the coverage of First-in-Class (FIC) innovative drugs in China reached 40%, with a notable presence of dual-antibody pipelines at the 2025 ASCO conference, indicating global academic recognition [2] Group 3 - As of July 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.58% of the index, with key players including Yunnan Baiyao (000538) and Pian Zai Huang (600436) [3]

Group 1 - The core viewpoint of the articles highlights the financial performance and market activity of Yiling Pharmaceutical Co., Ltd. as of August 15, 2025, indicating a mixed performance with a slight increase in stock price but a decrease in revenue [1][3] - As of the first quarter of 2025, the company's total operating revenue was 2.358 billion yuan, a year-on-year decrease of 6.52%, while the net profit attributable to shareholders was 326 million yuan, reflecting a year-on-year increase of 7.25% [1] - The company has a current ratio of 1.802, a quick ratio of 1.281, and a debt-to-asset ratio of 23.13%, indicating a stable liquidity position and low leverage [1] Group 2 - Yiling Pharmaceutical has made investments in 17 companies and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 628 trademark registrations and 597 patent registrations, indicating a strong focus on intellectual property [2] - Additionally, Yiling Pharmaceutical has obtained 739 administrative licenses, reflecting its compliance and operational capabilities [2]

Core Viewpoint - Yiling Pharmaceutical has received approval from the Macao Health Bureau for its innovative traditional Chinese medicine, Qifang Bitong Pian, marking a significant milestone in the development of traditional Chinese medicine in Macao [1][3]. Company Summary - Yiling Pharmaceutical's subsidiary, Yiling (Macao) Co., Ltd., has been granted the first registration certificate for an innovative traditional Chinese medicine by the Macao Health Bureau [1]. - Qifang Bitong Pian is designed to treat persistent allergic rhinitis, addressing symptoms such as sneezing, runny nose, nasal congestion, and fatigue [3]. - The company holds complete intellectual property rights for Qifang Bitong Pian, which is based on the theory of "lung and spleen deficiency" in allergic rhinitis treatment [3]. Industry Summary - The approval of Qifang Bitong Pian represents a new treatment option for patients with allergic rhinitis and revitalizes the application of traditional Chinese medicine in the field of otolaryngology [3]. - Yiling Pharmaceutical is leveraging modern high-tech innovations to drive the industrialization of traditional Chinese medicine, with 17 patented new drugs, including 11 listed in the national medical insurance directory [4]. - The company is advancing its research pipeline with two traditional Chinese medicines already submitted for production and six in clinical stages, alongside numerous hospital preparations as a reserve for new drug development [4].

Core Viewpoint - The announcement by the National Medical Products Administration regarding the optimization of clinical trial review and approval for innovative drugs is a significant positive development for the industry, particularly as it reduces the review time from 60 to 30 working days for innovative drug applications, including traditional Chinese medicine (TCM) [1] Group 1: Industry Overview - The recognition of TCM as an essential part of innovative drugs contrasts with the capital market's perception, which has not seen significant growth in TCM companies despite a surge in innovative drug stocks this year [1] - The modernization of TCM is gaining traction, supported by national policies, emphasizing the integration of traditional advantages with modern scientific techniques [3][4] Group 2: Company Profile - Yiling Pharmaceutical - Yiling Pharmaceutical is a leading innovative drug company with a focus on TCM, biopharmaceuticals, and health products, with TCM being the primary revenue and profit contributor [1] - As of the end of 2024, Yiling Pharmaceutical holds 17 patented TCM products covering eight major clinical disease systems, leading in the cardiovascular and respiratory disease treatment sectors [1] Group 3: Financial Performance - In 2024, Yiling Pharmaceutical's revenue from cardiovascular drugs exceeded 3.8 billion, while respiratory drugs accounted for less than 800 million, together representing over 70% of total revenue [9] - The company has experienced a decline in revenue over the past two years, primarily due to a significant drop in demand for its product Lianhua Qingwen post-pandemic [11] Group 4: Research and Development - Yiling Pharmaceutical has consistently ranked among the top in R&D investment within the A-share TCM sector, with annual R&D expenditures of approximately 895 million, 935 million, and 908 million over the past three years, representing 7.15%, 9.06%, and 13.94% of revenue respectively [5] - The company has achieved notable academic breakthroughs, including a landmark study published in a top medical journal demonstrating the efficacy of its product Tongxinluo in reducing cardiovascular events [6] Group 5: Growth Potential - Yiling Pharmaceutical's core competitive advantage lies in its founder's innovative theory on vascular diseases, which has attracted international research interest [12] - The company has five new drugs approved in the past five years, with four included in the medical insurance directory, indicating a strong pipeline for future growth [12] - The current market valuation of Yiling Pharmaceutical is estimated to be around 300 billion, with potential for significant appreciation as the market begins to recognize the value of innovative TCM [16]